Hyperhomocysteinemia in movement disorders: Current evidence and hypotheses

Current Vascular Pharmacology

Volumn 4, Issue 3, 2006, Pages 237-243

  Zoccolella, Stefano ^a   Martino, Davide ^a   Defazio, Giovanni ^a   Lamberti, Paolo ^a   Livrea, Paolo ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

B vitamins; Homocysteine; Huntington's disease; Levodopa; Movement disorders; Parkinson's disease; Primary dystonia

Indexed keywords

BIOLOGICAL MARKER; CARBAMAZEPINE; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; ESTROGEN DERIVATIVE; FOLIC ACID ANTAGONIST; HOMOCYSTEINE; LEVODOPA; METHOTREXATE; PHENYTOIN; THEOPHYLLINE; THIAZIDE DIURETIC AGENT; CYSTATHIONINE BETA SYNTHASE; DOPAMINE RECEPTOR STIMULATING AGENT; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ALZHEIMER DISEASE; COFFEE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DYSTONIA; HOMOCYSTINURIA; HUMAN; HUNTINGTON CHOREA; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; METHYLATION; MOTOR DYSFUNCTION; MULTIINFARCT DEMENTIA; NEUROLOGIC DISEASE; NEUROTRANSMISSION; PARKINSON DISEASE; REVIEW; STROKE; SYSTEMIC DISEASE; VASCULAR DISEASE; VITAMIN DEFICIENCY; ADOLESCENT; ADULT; ANIMAL; ARTICLE; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; ENZYMOLOGY; META ANALYSIS; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; ANIMALS; CASE-CONTROL STUDIES; CATECHOL O-METHYLTRANSFERASE; CYSTATHIONINE BETA-SYNTHASE; DOPAMINE AGENTS; DYSTONIA; HOMOCYSTEINE; HUMANS; HUNTINGTON DISEASE; HYPERHOMOCYSTEINEMIA; LEVODOPA; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MOVEMENT DISORDERS; PARKINSON DISEASE; PROSPECTIVE STUDIES;

EID: 33747824165     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016106777698414     Document Type: Review

References (78)

1. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma Homocysteine as a risk factor for vascular disease. JAMA 1995; 274: 1049-57.
2. Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, Weger M. DACH-LIGA Homocysteine V. DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med 2003; 41: 1392-403.
3. Haynes WG. Hyperhomocysteinemia, vascular function and atherosclerosis: effects of vitamins. Cardiovasc Drugs Ther 2002; 16: 391-9.
4. Kelly PJ, Rosand J, Kistler JP, Shih VE, Silveira S, Plomaritoglou A, et al. Homocysteine, MTHFR C677T polymorphism, and risk of ischemic stroke. Results of a meta-analysis. Neurology 2002; 59: 529-536.
5. Hankey GJ, Eikelboom JW. Homocysteine and stroke. Curr Opin Neurol 2001; 14: 95-102.
6. Seshadri S , Wolf PA. Homocysteine and the brain: vascular risk factor or neurotoxin? Lancet Neurol 2003; 2: 11.
7. Bostom AG, Rosenberg IH, Silbershatz H, Jacques PF, Selhub J, D'Agostino RB, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Int Med 1999; 131: 352-355.
8. Hankey GJ. Is homocysteine a causal and treatable risk factor for vascular diseases of the brain (cognitive impairment and stroke)? Ann Neurol 2002; 51: 279-281.
9. Eikelboom JW, Hankey GJ, Anand SS, Lofthouse E, Staples N, Baker RI. Association between high homocysteine and ischaemic stroke due to large and small artery disease but not other etiological subtypes of ischaemic stroke. Stroke 2000; 31: 1069-1075.
10. Gallucci M, Zanardo A, De Valentin L, Vianello A. Homocysteine in Alzheimer disease and Vascular dementia. Arch Geront Geriatr Suppl 2004; 9: 195-200.
11. McIlroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype and risk for stroke, vascular dementia and alzheimer disease in Northern Ireland. Stroke 2002; 33: 2351-2356.
12. Vermeer SE, vanDijk EJ, Koudstaal PJ, Oudkerk M, Hofman A, Clarke R, et al. Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam scan study. Ann Neurol 2002: 51: 285-289.
13. Vermeer SE, Prinds ND, den Hejer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 348: 1215- 1222.
14. den Heijer T, Vermeer SE, Clarke R, Oudkerk M, Koudstaal PJ, Hofman A, et al. Homocysteine and brain atrophy on MRI of non demented elderly. Brain 2003; 126: 170-175.
15. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma Homocysteine as a risk factor for dementia and vascular disease. N Eng J Med 2002; 346: 476-483.
16. Mattson MP, Shea TB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 2003; 26: 137-146.
17. Hogervorst E, Mendes Ribiero H, Molyneux A, Budge M, Smith AD. Plasma Homocysteine levels, cerebrovascular risk factor, and cerebral white matter changes (leukoaraiosis) in patients with alzheimer disease. Arch Neurol 2002; 59: 787-793.
18. Luchsinger JA, Tang MX, Shea S, Miller J, Green R, Mayeaux R. Plasma Homocysteine levels and risk of Alzheimer Disease. Neurology 2004; 62: 1972-1976.
19. Wang HX, Wahlin A, Basun H, Fastbom J, Winblad B, Fratiglioni L. Vitamin B12 and folate in relation to the development of Alzheimer's Disease. Neurology 2001; 56: 1188-1196.
20. Morris MS. Homocysteine and Alzheimer's disease. Lancet Neurol 2003; 3: 425-428.
21. Allain P, Le Bouil A, Cordillet E, LeQuay L, Begheri H, Montastruc JL. Sulfate and cysteine levels in the plasma of patients with Parkinson's Disease. Neurotoxicology 1995; 16: 527-529.
22. Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Przuntek H, Kretschmer A, et al. Elevated plasma levels of homocysteine in Parkinson's Disease. Eur Neurol 1998; 40: 225-227.
23. Muller T, Werne B, Fowler B, Kuhn W. Nigral endothelial dysfunction, homocysteine and Parkinson's Disease. Lancet 1999; 354: 126-127.
24. Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopa treated patients with PD. Neurology 2000; 55: 437-440.
25. Kuhn W, Hummel T, Woitalla D, Muller T. Plasma Homocysteine and MTHFR C677T genotype in levodopa treated patients with PD. Neurology 2001; 56: 281-282.
26. Brattstrom L. Plasma Homocysteine and MTHFR C677T genotype in levodopa treated patients with PD. Neurology 2001; 56: 281.
27. Blandini F, Fancellu R, Martignoni E, Mangiagalli A, Pacchetti C, Samuele A, et al. Plasma Homocysteine and L-Dopa metabolism in patients with Parkinson's Disease. Clin Chem 2001; 47: 1102-1104.
28. Muller T, Woitalla D, Hauptmann B, Fowler B, Kuhn W. Decrease of methionine and S-Adenozylmethionine and increase of homocysteine in treated patients with Parkinson's Disease. Neurosci Lett 2001; 308: 54-56.
29. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with Levodopa. Arch Neurol 2003; 60: 59-64.
30. Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA. Effects of L-Dopa on plasma homocysteine in PD patients. Relationship to B-vitamin status. Neurology 2003; 60: 1125-1129.
31. Yasui K, Nakaso K, Kowa H, Takeshima T, Nakashima K . Levodopa-induced hyperhomocysteinaemia in Parkinson's Disease. Acta Neurol Scand 2003; 108: 66-67.
32. Woitalla D, Kuhn W, Muller T. MTHFR C677T polymorphism, folic acid and hyperhomocysteinemia in levodopa treated patients with parkinson's disease. J Neural Transm Suppl 2004; 64: 15-20.
33. Lamberti P, Zoccolella S, Iliceto G, Armenise E, Fraddosio A, de Mari M, et al. Effects of levo-dopa and COMT Inhibitors on plasma Homocysteine in PD patients. Mov Disord 2005; 20: 69-72.
34. Nakaso K, Yasui K, Kowa H, Kusumi M, Ueda K, Yoshimoto Y, et al. Hypertrophy of IMC of carotid artery in Parkinson's Disease is associated with levodopa, homocysteine and MTHFR genotype. J Neurol Sci 2003; 207: 19-23.
35. O'Suilleabhain PE, Diaz-Arrastia R. Levodopa elevates homocysteine: is this a problem? Arch Neurol 2004; 61: 633-634.
36. O'Suilleabhain PE, Sung V, Hernandez C, Lacritz L, Dewey RB, Bottiglieri T, et al. Elevated plasma homocysteine levels in patients with parkinson's disease. Motor, affective and cognitive associations. Arch Neurol 2004; 61: 865-868.
37. Muller T, Renger K. Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Arch Neurol 2004; 61: 657-660.
38. Ozkan S, Colak O, Kutlu C, Ertan M, Alatas O. Plasma Homocysteine levels in pergolide treated parkinson's disease patients. Clin Neuropharmacol 2004; 27: 163-165.
39. O'Suilleabhain PE, Bottiglieri T, Dewey RB, Sharma S, Diaz-Arrastia R. Modest increase in plasma homocysteine follows levodopa initiation in parkinson's disease. Mov Disord 2004; 19: 1403-8.
40. Postuma RB. Lang A. Homocysteine and levodopa. Should parkinson disease patients receive preventative therapy? Neurology 2004; 63: 886-891.
41. Dzoljic E, Novakovic I, Mirkovic D, Todorovic Z, Prostran M, Kostic V. Homocysteine levels and MTHFR C67T genotype in patients with Parkinson's Disease with and without levodopa therapy. Mov Disord 2004; 19 (suppl 9): S235.
42. Zesiewicz TA, Giunta B, Hauser RA, Hoffman M, Wallach P, Sullivan KL. Levodopa induced hyperhomocysteinemia and cardiovascular dysfunction in Parkinson's Disease. Mov Disord 2004; 19 (suppl 9): S213.
43. Hassin Baer S, Cohen, O, Vakil E, Argov Z, Nitsan C, Sela BA, et al. Plasma Homocysteine and clinical characteristics in Parkinson's Disease. Mov Disord 2004; 19 (suppl 9): S162.
44. Siniscalchi A. Hyperhomocysteinemia in neurologic diseases. Recenti Prog Med 2004; 95: 371-375.
45. Sachdev P. Homocysteine in neuropsychiatric disorders. Rev Bras Psiquiatr 2004; 26: 50-56.
46. Lokk J. Treatment with levodopa can affect latent vitamin B12 and folic acid deficiency. Patients with Parkinson disease runt the risk of elevated homocysteine levels. Lakartdningen 2003; 100: 2674-2677.
47. Miller JW. Homocysteine , folate deficiency, and parkinson's Disease. Nutr Rev 2002; 60: 410-413.
48. Andrich J, Saft C, Arz A, Schneider B, Agelink MW, Kraus PH, et al. Hyperhomocysteinaemia in treated patients with Huntington's Disease. Mov Disord 2004; 19: 226-228.
49. Muller T, Woitalla D, Hunsdiek A, Kuhn W. Elevated plasma levels of homocysteine in dystonia. Acta Neurol Scand 2000; 101(6): 388-90.
50. Mueller UJ, Frick B, Fuchs D, Wenning GK, Poewe W, Mueller J. Homocysteine and serum markers of immune activation in dystonia. Mov Disord 2004; 19 (suppl 9): S108.
51. Rasmussen K, Moller J. Methodologies of testing. In: Carmel R, Jacobsen DW, eds. Homocysteine in Health and disease. New York. NY. Cambridge University Press; 2001: 199-201.
52. Ubbink JB, Hayward Vermaak WJ, Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr 1991; 565: 441-446.
53. Te Poele-Pothoff MTWB, van den Berg M, Franken DG, Franken DG, Boers GH, Jakobs C, et al. Three different methods for the determination of total homocysteine in plasma. Ann Clin Biochem 1995; 32: 218-220.
54. Daly D, Miller JW, Nadeau MR, Selhub J. The effect of L-dopa administration and folate deficiency on plasma homocysteine concentrations in rats. J Nutr Biochem 1997; 8: 634-640.
55. Miller JW, Shukitt-Hale B, Villalobos-Molina R, Nadeau MR, Selhub J, Joseph JA. Effect of L-Dopa and the catechol-O-methyltransferase Inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol 1997; 20: 55-66.
56. Gorell JM Johnson CC, Rybicki BA. Parkinson's disease and its comorbid disorders: analysis of michigan mortality data, 1970 to 1990. Neurology 1994; 44: 1865-1866.
57. Ben-Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clue to its etiology? J Neurol Neuros Psych 1995; 58: 293-299.
58. Levine RL, Jones JC, Nee N. Stroke and Parkinson's Disease. Stroke 1992; 23: 839-842.
59. Marttila RJ, Rinne UK. Arteriosclerosis, heredity, and some previous infections in the etiology of Parkinson's Disease. A case-control Study. Clin Neurol Neurosurg 1976; 79: 46-56.
60. Korten A, Lodder J, Vreeling F, Boreas A, van Raak L, Kessels F. Stroke and idiopathic parkinson's disease: does a shortage of dopamine offer protection against stroke? Mov Disord 2001; 16: 119-123.
61. McCann SJ, LeCouteur DG, Green AC, Brayne C, Johnson AG, Chan D, et al. The epidemiology of Parkinson's Disease in Australian population. Neuroepidemiology 1998; 17: 310-317.
62. Struck RK, Rodnitzky RL, Dobson JK. Stroke and its modification in Parkinson's Disease. Stroke 1990; 21: 1395-1399.
63. Jellinger KA. Prevalence of stroke in Parkinson's Disease. Mov Disord 2003; 18: 723-724.
64. Mastaglia FM, Johnsen RD, Kakulas BA. Prevalence of stroke in Parkinson's Disease: a postmortem study. Mov Disord 2002; 17: 772-774.
65. Hernan MA, Yakkouche B, Casamano-Isorna F, Gestal -Otero JJ. A meta-analysis of coffee drinking, cigarette smoking and the risk of Parkinson's Disease. Ann Neurol 2002; 52: 276-282.
66. Emre M. Dementia associated with Parkinson's Disease. Lancet Neurol 2003; 2: 229-237.
67. Boutell JM, Wood JD, Harper PS, Jones AJ. Huntington interacs with Cystathionine b-synthase. Hum Mol Gen 1998; 7: 371-378.
68. Sorensen SA, Fenger K. Causes of death in patients with Huntington's disease and in unaffected first degree relatives. J Med Genet 1992; 29: 911- 914.
69. Lanska DJ, Lavine L , Lanska MJ, Shoenberg BS. Huntington's disease mortality in the United States. Neurology 1988; 7: 371-378.
70. Fahn S, Bressman SB, Marsden CD. In: Fahn S, Marsden CD, DeLong MR Ed, Classification of Dystonia. Adv Neurol, Volume: 78, Philadeplphia, Lippincott-Raven Co. 1998: 1-10.
71. Lyon G, Adams RD, Kolodny EH. In: Lyon G , Adams RD , EH , Ed,Neurology of Hereditary Metabolic Diseases of Children. New York, St. Louis: McGraw-Hill Co. 1996: 177-281.
72. Ekinci B, Apaydin H, Vural M, Ozekmekci S. Two siblings with homocystinuria presenting with dystonia and parkinsonism. Mov Disord 2004; 19: 962-4.
73. Sibbing D, Asmus F, Konig IR, Tezenas du Montcel S, Vidailhet M, Sangla S, et al. Candidate gene studies in focal dystonia. Neurology 2003; 61:1097-101.
74. LeWitt PA, Nyholm D. New developments in levodopa therapy. Neurology 2004; 62(suppl 1): S9-S16.
75. Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 2002; 80: 101-110.
76. Rascol O, Fabre N. Dyskinesia: L-dopa-induced and tardive dyskinesia. Clin Neuropharmacol 2001; 24: 313-23.
77. May PC, Gray PN. L-Homocysteic acid as an alternative cytotoxin for studying glutamate induced cellular degeneration in Huntington's Disease and normal skin fibroblasts. Life Sci 1985; 37: 1483-1489.
78. He K, Merchant A, Rimm EB, Rosner BA, Stampfer MJ, Willett WC, Ascherio A. Folate, vitamin B6, and B12 intakes in relation to risk of stroke among men. Stroke 2004; 35:169-74.